Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE
15. Juli 2008 09:24 ET
|
Jerini AG
BERLIN, July 15, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the European Commission has granted the company marketing authorization for Firazyr(r) (Icatibant) in the treatment...
Jerini AG and Shire Limited Announce Strategic Partnership
03. Juli 2008 04:08 ET
|
Jerini AG
Shire Offers Euro 6.25 Per Share and Further Subscribes For Shares
in a Capital Increase
Takeover by Shire Ensures Successful Commercialization of...
Jerini to Submit Complete Response to the FDA for Icatibant in the Treatment of HAE
23. Juni 2008 08:42 ET
|
Jerini AG
BERLIN, June 23, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that following last week's communication with the U.S. Food and Drug Administration (FDA), the company will submit a...
Jerini AG Reports First Quarter 2008 Financial Results
15. Mai 2008 03:09 ET
|
Jerini AG
BERLIN, May 15, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results for the first quarter ended March 31, 2008. Under International Financial Reporting Standards (IFRS), revenues...
Jerini Receives Positive CHMP Opinion Recommending European Approval for Icatibant in the Treatment of HAE; FDA Issues Not Approvable Letter
24. April 2008 14:56 ET
|
Jerini AG
BERLIN, April 24, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the...
Ad Hoc: Jerini AG -- FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAE
24. April 2008 08:50 ET
|
Jerini AG
BERLIN, April 24, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) has received a not approvable letter from the FDA for its New Drug Application (NDA) for Icatibant in the treatment of hereditary...
Jerini Ophthalmic and PR Pharmaceuticals Sign Collaboration Agreement to Develop Sustained-Release Formulations for the Treatment of Eye Diseases
10. April 2008 14:13 ET
|
Jerini AG
BERLIN and FORT COLLINS, Colo., April 10, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) and PR Pharmaceuticals announced today a license and development agreement between Jerini Ophthalmic, Inc. (JOI),...
Jerini AG Reports Financial Results for Fiscal Year 2007
27. März 2008 04:20 ET
|
Jerini AG
Highlights:
* EUR 38.2 million in cash and cash equivalents as of
December 31, 2007
* Revenues in 2007 increased by 42 percent to EUR 18.6 million
* Marketing applications for...
Ad Hoc: Jerini Receives NDA Filing Acceptance and Priority Review From the FDA For Icatibant in the Treatment of HAE
21. Dezember 2007 03:22 ET
|
Jerini AG
BERLIN, Dec. 21, 2007 (PRIME NEWSWIRE) -- On December 20, 2007, Jerini AG (FSE:JI4) received filing acceptance of its New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema...
Jerini Receives NDA Filing Acceptance and Priority Review From the FDA For Icatibant in the Treatment of HAE
21. Dezember 2007 03:22 ET
|
Jerini AG
BERLIN, Dec. 21, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that its New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) has been accepted by the...